Pathogenesis of malignant eyelid tumors

Ophthalmology Clinics of North America

Volumn 13, Issue 4, 2000, Pages 557-569

  Kaltreider, Sara A ^b   Callahan, Claiborne ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BIOCHEMISTRY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURGERY; CHEMOSURGERY; EYELID TUMOR; HUMAN; KAPOSI SARCOMA; MEDICAL RESEARCH; MELANOMA; MERKEL CELL TUMOR; NONHUMAN; ONCOGENE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SEBACEOUS CARCINOMA; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; XERODERMA PIGMENTOSUM;

EID: 0033667748     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-1549(05)70217-0     Document Type: Article

References (114)

1. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies
2. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome
3. Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer
4. Patching together the genetics of Gorlin syndrome
5. Ras mutations in human melanoma: A marker of malignant progression
6. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis
7. The protein Id: A negative regulator of helix-loop-helix DNA binding-proteins
8. Genetic and environmental influences in the development of multiple primary melanoma
9. Carcinogenesis of cutaneous malignancies
10. Identification of herpesvirus-like DNA sequences in AIDS associated Kaposi's sarcoma
11. Essential role for oncogenic Ras in tumour maintainance
12. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer
13. Lymphoproliferative disorders of the ocular adnexa
14. Current treatment options for malignant melanoma
15. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota
16. A secreted FGF-binding protein can serve as the anti-ogenic switch in human cancer
17. Factors that influence DNA repair capacity of normal skin cancer-affected individuals
18. Detection of hyper-diploidy and chromosome breakage affecting the 1 (1 cenq12) region in lentigo malignant melanoma (LMM), superficial spreading melanoma (SSM) and congenital nevus (CN) cells in vitro by the multicolor FISH technique
19. Sebaceous gland carcinoma. Review of 40 cases
20. Treatment of malignant melanoma
21. Cutaneous melanoma risk and phenotypic changes in large congenital nevi: A follow-up study of 46 patients
22. The biology of melanoma
23. CD44 and melanocytic tumors: A possible role for standard CD44 in the epidermotropic spread of melanoma
24. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma
25. Developmental genes and cancer: Role of patched in basal cell carcinoma of the skin
26. The epidemiology of skin cancer
27. Squamous cell cancer: A practical approach
28. Kaposi's sarcoma
29. Sebaceous carcinoma tumor progression through mutational inactivation of p53
30. Cytogenetic follow-up in a case with a primary cutaneous melanoma and five metastatic lesions
31. Genetics of cutaneous melanoma and nevi
32. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma
33. Squamous cell carcinoma and its precursors: Clinical biology and molecular basis
34. Genetics of familial atypical multiple molemelanoma (FAMMM) syndrome in The Netherlands: How far have we come?
35. Merkel cell carcinoma diagnosis and treatment
36. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: Comparison with histopathological parameter
37. Gorlin syndrome: Identification of 4 novel germ-line mutations of the human patched (PTCH) gene. Mutations in brief no. 137
38. Prognostic significance of allelic losses in primary melanoma
39. Identification of two distinct deletion targets at 11 q23 in cutaneous malignant melanoma
40. Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi's sarcoma: 15-year lessons from AIDS
41. Identification of URIM, a novel gene up-regulated in metastasis
42. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma vaccine
43. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis
44. Id genes in cancer
45. The role of syndecan-1 in malignancies
46. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A
47. Ocular-adnexal lymphoid tumors: A clinicopathologic and molecular genetic study of 77 patients
48. AIDS related Kaposi's sarcoma: A template for the translation of molecular pathogenesis into targeted therapeutic approaches
49. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for MSH2 mutations
50. Cytogenetic study of a Merkel cell carcinoma
51. Xeroderma pigmentosum
52. Squamous and basal cell carcinoma in heart transplant recipients
53. Radiotherapy in the management of epidemic Kaposi's sarcoma of the oral cavity, the eyelid and the genitals
54. Principles of cancer immunology and immunotherapy
55. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma
56. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic
57. Mutation of the CDKN2A 5'UTR creates an aberrant initiation codon and predisposes to melanoma
58. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein
59. Squamous cell carcinoma of the eyelid and the acquired immunodeficiency syndrome
60. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorogenesis of sporadic malignant melanomas
61. Sunlight and melanoma: An answer from MTS1
62. Characterization of p53 gene mutations in basal cell carcinomas: Comparison between sun-exposed and less-exposed skin areas
63. UV induced immunosuppression and skin cancers
64. An analysis of UVA emissions from sunlamps and the potential importance for melanoma
65. Biology of basal cell carcinoma: II
66. Merkel cell carcinoma and melanoma: Etiological similarities and differences
67. Basal cell carcinomas
68. Merkel cells participate in the induction and alignment of epidermal ends of arrector pili muscles of human fetal skin
69. 9p21 deletion in primary melanoma
70. Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma
71. Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization
72. Multimodality management of Merkel cell carcinoma
73. Gene therapy with autologous, interleukin 2-secreting tumor celia in patients with malignant melanoma
74. Heterogeneity of HLA-Ggene transcription and protein expression in malignant melanoma biopsies
75. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
76. Widespread microsatellite instability in sebaceous tumours of patients with the Muir-Torre syndrome
77. Evidence of UV induction of CDKN2 mutations in melanoma ceil lines
78. Toxicity and feasibility of adjuvant high-dose interferon alpha 2b in patients with melanoma in clinical oncologic practice
79. Spontaneous intestinal carcinomas and skin neoplasms in Msh2 deficient mice
80. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MCIR, and TRP-2 in vaccine-treated melanoma patients
81. Functional localization of a melanoma tumor suppressor gene to a small (
82. Pathogenesis of cutaneous T-cell lymphoma: Implications for the use of recombinant cytokines and photopheresis
83. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
84. Parallel risk assessment of melanoma and basal cell carcinoma: Skin characteristics and sun exposure
85. Four-eyelid sebaceous cell carcinoma following radiation
86. HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma
87. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development
88. Induction of programmed ceil death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin
89. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas
90. Ultraviolet specific mutations in p53 gene in skin tumors in xeroderma pigmentosum patients
91. Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of pro-gelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts
92. Molecular biology of human melanoma development and progression
93. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role
94. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
95. The systemic treatment of AIDS-related Kaposi's sarcoma
96. A Muir-Torre syndrome family
97. The naevoid basal-cell carcinoma syndrome (Gorlin syndrome) is a chromosomal instability syndrome
98. Paditaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: Current and future directions
99. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma
100. The effects of splice mutations in patients with naevoid basal cell carcinoma syndrome
101. Inhibition of transforming growth factor alpha stimulation of human squamous cell carcinoma of the head and neck with anti-TGF-alpha antibodies and tyrphostin
102. Cytogenetic studies in primary and metastatic neuroendocrine Merkel cell carcinoma
103. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study
104. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study
105. Deletion analysis of the adenomatous polyposis coli and PTCH gene loci in patients with sporadic and nevoid basal cell carcinoma syndrome-associated medulloblastoma
106. Virtually 100% of melanoma ceil lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets
107. Functional reassessment of P16 variants using a transfection-based assay
108. Association of cutaneous malignant melanoma with intermittent exposure to ultraviolet radiation: Results of a case-control study in Ontario, Canada
109. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
110. Molecular basis of the nevoid basal cell carcinoma syndrome
111. Most germ-line mutations in the nevoid basal ceil carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident
112. Sunbyn and p53 in the onset of skin cancer
113. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: A maximum likelihood combined linkage and association analysis in twins and their sibs
114. Sebaceous carcinoma of the eyelid: A clinicopathological study